Treatment With Donepezil of Chronic Aphasia and Sensorimotor Deficits Associated to Cerebrovascular Accidents: a Double-Blind,Placebo-Controlled, Randomized Parallel Trial. View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2003-2005

ABSTRACT

- Aphasia (impairment of language function due to brain damage)may be treated with speech-language therapy and drugs. Several drugs have been studied but with limited success. - Recent data suggest that the neurotransmitter acetylcholine may be reduced in brain damaged subjects and that drugs that stimulates acetylcholine activity may help recovery of aphasic deficits particularly when paired with speech-language therapy. - Recent evidence indicates that medicaments acting on the neurotransmitter acetylcholine may promote improvement of aphasic deficits and our previous open-label study of donepezil in post-stroke aphasia showed benefits in all patients and observed benefit were long-lasting (6 months).This study will test the safety and efficacy of donepezil (an agent acting on acetylcholine)in subjects with stroke-related chronic aphasia (more than 1 yr of evolution). Detailed Description - Prior clinical information of donepezil treatment of post-stroke aphasia comes from single-case studies, small case-series and an open-label study. In addition, an extension phase of a small open-label study also suggest that the efficacy of donepezil in chronic post-stroke apahsia is maintained at long-term follow-up. These data collectively suggest that in post-stroke donepezil is effective and well-tolerated with a limited potential for causing clinically significant interactions when prescribed with other medications. However, these results are preliminary and should be judged parsimoniously until randomized controlled trials will be performed.Moreover, recent data by our group also showed that donepezil may improve sensorimotor deficits (hemiparesis)in some patients. - The use of acetylcholinesterase inhibitors such as donepezil in post-stroke may be justified because in vivo and postmortem studies have shown that patients with vascular dementia and lesions in subcortical and cortical structures have deficient cholinergic neurotransmission that results from interruption of cholinergic pathways linking the basal forebrain with the cerebral cortex, including the perisylvian language area.In addition, two large-scale randomized controlled trials in patients pure vascular dementia and vascular cognitive impairment found that donepezil was significantly superior to placebo on cognition, global function and activities of daily living.And the most noticeable benefits of donepezil over placebo at doses of 5-mg and 10-mg were found on the Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-Cog/11), an assessment instrument highly reliant upon language variables (6 out of 11 items). - We evaluated the efficacy of donepezil in patients with chronic aphasia associated with stroke.This is a 20-week, randomized, placebo-controlled, double-blind parallel study that enrolled aphasic patient with more than one year of evolution. During the study all patients continued receiving two hours weekly of conventional speech-language therapy. Patients were randomized in an 1:1 ratio to donepezil, 5-mg/day, for the first 4 weeks, followed by forced dose escalation to 10-mg/day thereafter (n =13), or placebo (n = 13) and then a 4 week washout period. The primary efficacy measures were the Aphasia Quotient (AQ) of the Western Aphasia Battery and the Communicative Activity Log. Secondary efficacy measures included selected subtests of the Psycholinguistic Assessment of Language Processing in Aphasia that examined phonological and lexical-semantic domains and the Stroke Aphasia Depression Questionnaire. More... »

URL

https://clinicaltrials.gov/show/NCT00196690

Related SciGraph Publications

  • 2005-02. Poststroke Aphasia in DRUGS & AGING
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3120", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3053", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }
        ], 
        "description": "- Aphasia (impairment of language function due to brain damage)may be treated with speech-language therapy and drugs. Several drugs have been studied but with limited success. - Recent data suggest that the neurotransmitter acetylcholine may be reduced in brain damaged subjects and that drugs that stimulates acetylcholine activity may help recovery of aphasic deficits particularly when paired with speech-language therapy. - Recent evidence indicates that medicaments acting on the neurotransmitter acetylcholine may promote improvement of aphasic deficits and our previous open-label study of donepezil in post-stroke aphasia showed benefits in all patients and observed benefit were long-lasting (6 months).This study will test the safety and efficacy of donepezil (an agent acting on acetylcholine)in subjects with stroke-related chronic aphasia (more than 1 yr of evolution).\n\nDetailed Description\n- Prior clinical information of donepezil treatment of post-stroke aphasia comes from single-case studies, small case-series and an open-label study. In addition, an extension phase of a small open-label study also suggest that the efficacy of donepezil in chronic post-stroke apahsia is maintained at long-term follow-up. These data collectively suggest that in post-stroke donepezil is effective and well-tolerated with a limited potential for causing clinically significant interactions when prescribed with other medications. However, these results are preliminary and should be judged parsimoniously until randomized controlled trials will be performed.Moreover, recent data by our group also showed that donepezil may improve sensorimotor deficits (hemiparesis)in some patients. - The use of acetylcholinesterase inhibitors such as donepezil in post-stroke may be justified because in vivo and postmortem studies have shown that patients with vascular dementia and lesions in subcortical and cortical structures have deficient cholinergic neurotransmission that results from interruption of cholinergic pathways linking the basal forebrain with the cerebral cortex, including the perisylvian language area.In addition, two large-scale randomized controlled trials in patients pure vascular dementia and vascular cognitive impairment found that donepezil was significantly superior to placebo on cognition, global function and activities of daily living.And the most noticeable benefits of donepezil over placebo at doses of 5-mg and 10-mg were found on the Alzheimer\u2019s Disease Assessment Scale-cognitive subscale (ADAS-Cog/11), an assessment instrument highly reliant upon language variables (6 out of 11 items). - We evaluated the efficacy of donepezil in patients with chronic aphasia associated with stroke.This is a 20-week, randomized, placebo-controlled, double-blind parallel study that enrolled aphasic patient with more than one year of evolution. During the study all patients continued receiving two hours weekly of conventional speech-language therapy. Patients were randomized in an 1:1 ratio to donepezil, 5-mg/day, for the first 4 weeks, followed by forced dose escalation to 10-mg/day thereafter (n =13), or placebo (n = 13) and then a 4 week washout period. The primary efficacy measures were the Aphasia Quotient (AQ) of the Western Aphasia Battery and the Communicative Activity Log. Secondary efficacy measures included selected subtests of the Psycholinguistic Assessment of Language Processing in Aphasia that examined phonological and lexical-semantic domains and the Stroke Aphasia Depression Questionnaire.", 
        "endDate": "2005-03-01T00:00:00Z", 
        "id": "sg:clinicaltrial.NCT00196690", 
        "keywords": [
          "donepezil", 
          "aphasia", 
          "sensorimotor deficit", 
          "stroke", 
          "Double-Blind", 
          "parallel", 
          "impairment", 
          "language function", 
          "brain damage", 
          "Language Therapy", 
          "drug", 
          "limited success", 
          "recent data", 
          "neurotransmitter acetylcholine", 
          "brain", 
          "acetylcholine", 
          "recovery", 
          "aphasic", 
          "Recent evidence", 
          "improvement", 
          "open-label study", 
          "post stroke", 
          "benefit", 
          "patient", 
          "safety", 
          "efficacy", 
          "agent", 
          "evolution", 
          "clinical information", 
          "single case study", 
          "case series", 
          "extension", 
          "significant interaction", 
          "medication", 
          "randomized controlled trial", 
          "Paresis", 
          "acetylcholinesterase inhibitor", 
          "vivo", 
          "postmortem study", 
          "vascular dementia", 
          "lesion", 
          "cortical structure", 
          "cholinergic neurotransmission", 
          "interruption", 
          "cholinergic pathway", 
          "basal forebrain", 
          "cerebral cortex", 
          "language area", 
          "vascular cognitive impairment", 
          "placebo", 
          "cognition", 
          "global function", 
          "dose", 
          "Alzheimer's", 
          "subscales", 
          "assessment instrument", 
          "language", 
          "parallel study", 
          "aphasic patient", 
          "dose escalation", 
          "washout period", 
          "primary efficacy", 
          "quotient", 
          "western", 
          "log", 
          "efficacy measure", 
          "language processing", 
          "lexical semantics", 
          "questionnaire"
        ], 
        "name": "Treatment With Donepezil of Chronic Aphasia and Sensorimotor Deficits Associated to Cerebrovascular Accidents: a Double-Blind,Placebo-Controlled, Randomized Parallel Trial.", 
        "sameAs": [
          "https://app.dimensions.ai/details/clinical_trial/NCT00196690"
        ], 
        "sdDataset": "clinical_trials", 
        "sdDatePublished": "2019-03-07T15:21", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "file:///pack/app/us_ct_data_00001.json", 
        "sponsor": [
          {
            "id": "https://www.grid.ac/institutes/grid.410513.2", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.10215.37", 
            "type": "Organization"
          }
        ], 
        "startDate": "2003-02-01T00:00:00Z", 
        "subjectOf": [
          {
            "id": "sg:pub.10.2165/00002512-200522020-00006", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1013306810", 
              "https://doi.org/10.2165/00002512-200522020-00006"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "type": "MedicalStudy", 
        "url": "https://clinicaltrials.gov/show/NCT00196690"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT00196690'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT00196690'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT00196690'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT00196690'


     

    This table displays all metadata directly associated to this object as RDF triples.

    97 TRIPLES      16 PREDICATES      87 URIs      78 LITERALS      1 BLANK NODES

    Subject Predicate Object
    1 sg:clinicaltrial.NCT00196690 schema:about anzsrc-for:3053
    2 anzsrc-for:3120
    3 schema:description - Aphasia (impairment of language function due to brain damage)may be treated with speech-language therapy and drugs. Several drugs have been studied but with limited success. - Recent data suggest that the neurotransmitter acetylcholine may be reduced in brain damaged subjects and that drugs that stimulates acetylcholine activity may help recovery of aphasic deficits particularly when paired with speech-language therapy. - Recent evidence indicates that medicaments acting on the neurotransmitter acetylcholine may promote improvement of aphasic deficits and our previous open-label study of donepezil in post-stroke aphasia showed benefits in all patients and observed benefit were long-lasting (6 months).This study will test the safety and efficacy of donepezil (an agent acting on acetylcholine)in subjects with stroke-related chronic aphasia (more than 1 yr of evolution). Detailed Description - Prior clinical information of donepezil treatment of post-stroke aphasia comes from single-case studies, small case-series and an open-label study. In addition, an extension phase of a small open-label study also suggest that the efficacy of donepezil in chronic post-stroke apahsia is maintained at long-term follow-up. These data collectively suggest that in post-stroke donepezil is effective and well-tolerated with a limited potential for causing clinically significant interactions when prescribed with other medications. However, these results are preliminary and should be judged parsimoniously until randomized controlled trials will be performed.Moreover, recent data by our group also showed that donepezil may improve sensorimotor deficits (hemiparesis)in some patients. - The use of acetylcholinesterase inhibitors such as donepezil in post-stroke may be justified because in vivo and postmortem studies have shown that patients with vascular dementia and lesions in subcortical and cortical structures have deficient cholinergic neurotransmission that results from interruption of cholinergic pathways linking the basal forebrain with the cerebral cortex, including the perisylvian language area.In addition, two large-scale randomized controlled trials in patients pure vascular dementia and vascular cognitive impairment found that donepezil was significantly superior to placebo on cognition, global function and activities of daily living.And the most noticeable benefits of donepezil over placebo at doses of 5-mg and 10-mg were found on the Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-Cog/11), an assessment instrument highly reliant upon language variables (6 out of 11 items). - We evaluated the efficacy of donepezil in patients with chronic aphasia associated with stroke.This is a 20-week, randomized, placebo-controlled, double-blind parallel study that enrolled aphasic patient with more than one year of evolution. During the study all patients continued receiving two hours weekly of conventional speech-language therapy. Patients were randomized in an 1:1 ratio to donepezil, 5-mg/day, for the first 4 weeks, followed by forced dose escalation to 10-mg/day thereafter (n =13), or placebo (n = 13) and then a 4 week washout period. The primary efficacy measures were the Aphasia Quotient (AQ) of the Western Aphasia Battery and the Communicative Activity Log. Secondary efficacy measures included selected subtests of the Psycholinguistic Assessment of Language Processing in Aphasia that examined phonological and lexical-semantic domains and the Stroke Aphasia Depression Questionnaire.
    4 schema:endDate 2005-03-01T00:00:00Z
    5 schema:keywords Alzheimer's
    6 Double-Blind
    7 Language Therapy
    8 Paresis
    9 Recent evidence
    10 acetylcholine
    11 acetylcholinesterase inhibitor
    12 agent
    13 aphasia
    14 aphasic
    15 aphasic patient
    16 assessment instrument
    17 basal forebrain
    18 benefit
    19 brain
    20 brain damage
    21 case series
    22 cerebral cortex
    23 cholinergic neurotransmission
    24 cholinergic pathway
    25 clinical information
    26 cognition
    27 cortical structure
    28 donepezil
    29 dose
    30 dose escalation
    31 drug
    32 efficacy
    33 efficacy measure
    34 evolution
    35 extension
    36 global function
    37 impairment
    38 improvement
    39 interruption
    40 language
    41 language area
    42 language function
    43 language processing
    44 lesion
    45 lexical semantics
    46 limited success
    47 log
    48 medication
    49 neurotransmitter acetylcholine
    50 open-label study
    51 parallel
    52 parallel study
    53 patient
    54 placebo
    55 post stroke
    56 postmortem study
    57 primary efficacy
    58 questionnaire
    59 quotient
    60 randomized controlled trial
    61 recent data
    62 recovery
    63 safety
    64 sensorimotor deficit
    65 significant interaction
    66 single case study
    67 stroke
    68 subscales
    69 vascular cognitive impairment
    70 vascular dementia
    71 vivo
    72 washout period
    73 western
    74 schema:name Treatment With Donepezil of Chronic Aphasia and Sensorimotor Deficits Associated to Cerebrovascular Accidents: a Double-Blind,Placebo-Controlled, Randomized Parallel Trial.
    75 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT00196690
    76 schema:sdDatePublished 2019-03-07T15:21
    77 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    78 schema:sdPublisher Nb63532f96b0048f1acf69a5f89d3c362
    79 schema:sponsor https://www.grid.ac/institutes/grid.10215.37
    80 https://www.grid.ac/institutes/grid.410513.2
    81 schema:startDate 2003-02-01T00:00:00Z
    82 schema:subjectOf sg:pub.10.2165/00002512-200522020-00006
    83 schema:url https://clinicaltrials.gov/show/NCT00196690
    84 sgo:license sg:explorer/license/
    85 sgo:sdDataset clinical_trials
    86 rdf:type schema:MedicalStudy
    87 Nb63532f96b0048f1acf69a5f89d3c362 schema:name Springer Nature - SN SciGraph project
    88 rdf:type schema:Organization
    89 anzsrc-for:3053 schema:inDefinedTermSet anzsrc-for:
    90 rdf:type schema:DefinedTerm
    91 anzsrc-for:3120 schema:inDefinedTermSet anzsrc-for:
    92 rdf:type schema:DefinedTerm
    93 sg:pub.10.2165/00002512-200522020-00006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013306810
    94 https://doi.org/10.2165/00002512-200522020-00006
    95 rdf:type schema:CreativeWork
    96 https://www.grid.ac/institutes/grid.10215.37 schema:Organization
    97 https://www.grid.ac/institutes/grid.410513.2 schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...